Sfoglia per Autore
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms
2010 A. Rambaldi, C.M. Dellacasa, G. Finazzi, A. Carobbio, M.L. Ferrari, P. Guglielmelli, E. Gattoni, S. Salmoiraghi, M.C. Finazzi, S. Di Tollo, C. D'Urzo, A.M. Vannucchi, G. Barosi, T. Barbui
Front-line therapy in polycythemia vera and essential thrombocythemia
2012 T. Barbui, M.C. Finazzi, G. Finazzi
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN
2012 E. Antonioli, P. Guglielmelli, L. Pieri, M. Finazzi, E. Rumi, V. Martinelli, N. Vianelli, M. Luigia Randi, I. Bertozzi, V. De Stefano, T. Za, E. Rossi, M. Ruggeri, E. Elli, R. Cacciola, E. Cacciola, E. Pogliani, F. Rodeghiero, M. Baccarani, F. Passamonti, G. Finazzi, A. Rambaldi, A. Bosi, M. Cazzola, T. Barbui, A.M. Vannucchi
A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy
2013 G. Finazzi, A.M. Vannucchi, V. Martinelli, M. Ruggeri, F. Nobile, G. Specchia, E.M. Pogliani, O.M. Olimpieri, G. Fioritoni, C. Musolino, D. Cilloni, P. Sivera, G. Barosi, M.C. Finazzi, S.D. Tollo, T. Demuth, T. Barbui, A. Rambaldi
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia : a report from the MPN subcommittee of the chronic malignancies working party of the European group for blood and marrow transplantation
2014 F. Lussana, A. Rambaldi, M.C. Finazzi, A. van Biezen, M. Scholten, E. Oldani, A. Carobbio, S. Iacobelli, J. Finke, A. Nagler, L. Volin, T. Lamy, R. Arnold, M. Mohty, M. Michallet, T. de Witte, E. Olavarria, N. Kröger
A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy
2014 J. Golay, A. D'Amico, G. Borleri, M. Bonzi, R. Valgardsdottir, R. Alzani, S. Cribioli, C. Albanese, E. Pesenti, M.C. Finazzi, G. Quaresmini, D. Nagorsen, M. Introna, A. Rambaldi
Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms : an European Leukemia Net study
2014 I. Martinelli, V. De Stefano, A. Carobbio, M.L. Randi, C. Santarossa, A. Rambaldi, M.C. Finazzi, F. Cervantes, E. Arellano Rodrigo, S. Rupoli, L. Canafoglia, A. Tieghi, L. Facchini, S. Betti, A.M. Vannucchi, L. Pieri, R. Cacciola, E. Cacciola, A. Cortelezzi, A. Iurlo, E.M. Pogliani, E.M. Elli, A. Spadea, T. Barbui
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis
2015 M.C. Finazzi, A. Carobbio, F. Cervantes, I.M. Isola, A.M. Vannucchi, P. Guglielmelli, A. Rambaldi, G. Finazzi, G. Barosi, T. Barbui
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists
2016 V. De Stefano, M. Ruggeri, F. Cervantes, A. Alvarez-Larran, A. Iurlo, M.L. Randi, E. Elli, M.C. Finazzi, G. Finazzi, E. Zetterberg, N. Vianelli, G. Gaidano, E. Rossi, S. Betti, I. Nichele, D. Cattaneo, M. Palova, M.H. Ellis, R. Cacciola, A. Tieghi, J.C. Hernandez-Boluda, E. Pungolino, G. Specchia, D. Rapezzi, A. Forcina, C. Musolino, A. Carobbio, M. Griesshammer, E. Sant'Antonio, A.M. Vannucchi, T. Barbui
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
2016 V. De Stefano, A.M. Vannucchi, M. Ruggeri, F. Cervantes, A. Alvarez-Larrán, A. Iurlo, M.L. Randi, L. Pieri, E. Rossi, P. Guglielmelli, S. Betti, E. Elli, M.C. Finazzi, G. Finazzi, E. Zetterberg, N. Vianelli, G. Gaidano, I. Nichele, D. Cattaneo, M. Palova, M.H. Ellis, E. Cacciola, A. Tieghi, J.C. Hernandez-Boluda, E. Pungolino, G. Specchia, D. Rapezzi, A. Forcina, C. Musolino, A. Carobbio, M. Griesshammer, T. Barbui
Detection of driver and subclonal mutations in myelofibrosis : clinical impact on pharmacologic and transplant based treatment strategies
2017 M.C. Finazzi, F. Lussana, S. Salmoiraghi, O. Spinelli, A. Rambaldi
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera : a propensity-matched study
2017 T. Barbui, A.M. Vannucchi, G. Finazzi, M.C. Finazzi, A. Masciulli, A. Carobbio, A. Ghirardi, G. Tognoni
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms
2018 V. De Stefano, A. Carobbio, V. Di Lazzaro, P. Guglielmelli, A. Iurlo, M.C. Finazzi, E. Rumi, F. Cervantes, E.M. Elli, M.L. Randi, M. Griesshammer, F. Palandri, M. Bonifacio, J.-. Hernandez-Boluda, R. Cacciola, P. Miroslava, G. Carli, E. Beggiato, M.H. Ellis, C. Musolino, G. Gaidano, D. Rapezzi, A. Tieghi, F. Lunghi, G.G. Loscocco, D. Cattaneo, A. Cortelezzi, S. Betti, E. Rossi, G. Finazzi, B. Censori, M. Cazzola, M. Bellini, E. Arellano-Rodrigo, I. Bertozzi, P. Sadjadian, N. Vianelli, L. Scaffidi, M. Gomez, E. Cacciola, A.M. Vannucchi, T. Barbui
Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts
2018 A. Tefferi, M. Mudireddy, F. Mannelli, K.H. Begna, M.M. Patnaik, C.A. Hanson, R.P. Ketterling, N. Gangat, M. Yogarajah, V. De Stefano, F. Passamonti, V. Rosti, M.C. Finazzi, A. Rambaldi, A. Bosi, P. Guglielmelli, A. Pardanani, A.M. Vannucchi
Busulfan or thiotepa based conditioning in myelofibrosis: A phase II multicenter randomized study from the GITMO group
2019 F. Patriarca, A. Masciulli, A. Bacigalupo, S. Bregante, C. Pavoni, M.C. Finazzi, A. Bosi, D. Russo, F. Narni, G. Messina, E.P. Alessandrino, A.M. Carella, G. Milone, B. Bruno, S. Mammoliti, B. Bruno, R. Fanin, F. Bonifazi, A. Rambaldi
A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis
2019 J. Mascarenhas, H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, M.E. Salama, R.S. Weinberg, R. Rampal, J.D. Goldberg, R. Mesa, A.C. Dueck, R. Hoffman
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea
2019 A. Yacoub, J. Mascarenhas, H. Kosiorek, J.T. Prchal, D. Berenzon, M.R. Baer, E. Ritchie, R.T. Silver, C. Kessler, E. Winton, M.C. Finazzi, A. Rambaldi, A.M. Vannucchi, D. Leibowitz, D. Rondelli, M.O. Arcasoy, R. Catchatourian, J. Vadakara, V. Rosti, E. Hexner, M. Kremyanskaya, L. Sandy, J. Tripodi, V. Najfeld, N. Farnoud, E. Papaemmanuil, M. Salama, R. Singer-Weinberg, R. Rampal, J.D. Goldberg, T. Barbui, R. Mesa, A.C. Dueck, R. Hoffman
Second primary malignancies in ruxolitinib-treated myelofibrosis : real-world evidence from 219 consecutive patients
2019 M. Maffioli, T. Giorgino, B. Mora, A. Iurlo, E. Elli, M.C. Finazzi, M. Caramella, E. Rumi, M.C. Carraro, N. Polverelli, M. D'Adda, S. Malato, M. Rossi, A. Molteni, A. Vismara, C. Sissa, F. Spina, M. Anghilieri, D. Cattaneo, R. Renso, M. Bellini, M.L. Pioltelli, C. Cavalloni, D. Barraco, R. Accetta, L. Bertu, M.G.D. Porta, F. Passamonti
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
2020 P. Guglielmelli, A. Carobbio, E. Rumi, V. De Stefano, L. Mannelli, F. Mannelli, G. Rotunno, G. Coltro, S. Betti, C. Cavalloni, M.C. Finazzi, J. Thiele, M. Cazzola, A.M. Vannucchi, T. Barbui
Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival
2020 M.C. Finazzi, C. Boschini, C. Craddock, A. Rambaldi, J. Ward, R.K. Malladi
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile